Methyl 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylate is a 4-Methylthiazole-5-carboxylic Acid derivative as a potential inhibitor of mucin onco proteins for breast cancer therapy.Also, it is derived from Febuxostat (F229000), which is a xanthine oxidase/xanthine dehydrogenase inhibitor and used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.
